Thursday, October 25, 2018 10:48:19 AM
1.) haven't seen any form 4s regarding management selling off any shares so they are on the edge of getting burned at their last purchase price of .72 range without any visually stimulating or imaginative updates.
2.) Institutional investors per the last quarterly update ending 6/30 now own significantly less by 1/3 per the dilution rate and increased sharecount, unless they have bought more shares which is unlikely.
If fins drop tomorrow today could be a solid buy point, granted it appears that more money has funded R&D then actual revenue, so it's possible they are net negative. OR...
Average down and expect this as a long hold, but I personally think ZAcksbys 7$ target is still in effect, just not sure which quarter, or if the dilution was factored in.
Recent OGEN News
- Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards • Business Wire • 04/19/2024 09:50:00 PM
- Oragenics, Inc. Files 10K and Provides Company Update • Business Wire • 04/01/2024 01:05:00 PM
- Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion • Business Wire • 03/18/2024 11:00:00 AM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 03/06/2024 09:24:29 PM
- Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion • Business Wire • 03/05/2024 12:45:00 PM
- Oragenics Announces Closing of Public Offering • Business Wire • 03/01/2024 09:04:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/29/2024 09:41:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 02:03:04 PM
- Oragenics Announces Pricing of Public Offering • Business Wire • 02/28/2024 02:25:00 AM
- Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses • Edgar (US Regulatory) • 02/27/2024 10:09:12 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/27/2024 10:04:34 PM
- Oragenics Announces Proposed Public Offering • Business Wire • 02/27/2024 09:33:00 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 02/13/2024 01:06:23 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/12/2024 09:45:18 PM
- Oragenics, Inc. Announces Leadership Transition • Business Wire • 02/12/2024 09:41:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/07/2024 01:00:18 PM
- Oragenics, Inc. Announces Expiration of Its Investment Banking Engagement Agreement • Business Wire • 02/07/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/05/2024 01:00:23 PM
- Oragenics, Inc. Preparing for Phase II Clinical Trials to Treat Concussion • Business Wire • 02/05/2024 01:00:00 PM
- Oragenics Announces Termination of At-The-Market Offering Program • Business Wire • 01/23/2024 10:34:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/23/2024 10:18:59 PM
- Form 5 - Annual statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/22/2024 10:30:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 02:10:51 PM
- Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses • Edgar (US Regulatory) • 01/16/2024 02:08:13 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 01/16/2024 02:04:40 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM